AC Immune SA (ACIU)
3.29
+0.05
(+1.54%)
USD |
NASDAQ |
Nov 21, 16:00
3.285
0.00 (0.00%)
Pre-Market: 20:00
AC Immune Total Assets (Quarterly): 290.33M for Sept. 30, 2024
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | 290.33M |
June 30, 2024 | 264.24M |
March 31, 2024 | 185.40M |
December 31, 2023 | 217.65M |
September 30, 2023 | 156.28M |
June 30, 2023 | 173.73M |
March 31, 2023 | 185.17M |
December 31, 2022 | 200.55M |
September 30, 2022 | 210.79M |
June 30, 2022 | 227.16M |
March 31, 2022 | 255.10M |
December 31, 2021 | 286.01M |
September 30, 2021 | 217.66M |
June 30, 2021 | 229.20M |
March 31, 2021 | 242.00M |
December 31, 2020 | 273.26M |
September 30, 2020 | 279.05M |
June 30, 2020 | 287.31M |
Date | Value |
---|---|
March 31, 2020 | 300.22M |
December 31, 2019 | 308.85M |
September 30, 2019 | 318.12M |
June 30, 2019 | 303.24M |
March 31, 2019 | 314.24M |
December 31, 2018 | 199.64M |
September 30, 2018 | 212.69M |
June 30, 2018 | 112.81M |
March 31, 2018 | 125.86M |
December 31, 2017 | 135.52M |
September 30, 2017 | 129.22M |
June 30, 2017 | 137.39M |
March 31, 2017 | 144.52M |
December 31, 2016 | 153.41M |
September 30, 2016 | 166.29M |
June 30, 2016 | 105.42M |
March 31, 2016 | 76.21M |
December 31, 2015 | 80.87M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
156.28M
Minimum
Sep 2023
308.85M
Maximum
Dec 2019
239.50M
Average
235.60M
Median
Total Assets (Quarterly) Benchmarks
CRISPR Therapeutics AG | 2.256B |
Addex Therapeutics Ltd | 15.24M |
NLS Pharmaceutics Ltd | 1.194M |
Molecular Partners AG | 183.31M |
MoonLake Immunotherapeutics | 518.21M |
Total Assets (Quarterly) Related Metrics
Total Liabilities (Quarterly) | 135.61M |
Shareholders Equity (Quarterly) | 154.72M |
Current Ratio | 1.858 |